ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72

ESSENCE试验数据显示，在第72周时，接受司美格鲁肽治疗的参与者中有63%实现了脂肪性肝炎的缓解且肝纤维化未恶化，而接受安慰剂治疗的参与者中这一比例为34%。

Novo Nordisk has announced that Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2.4 mg) as the first approved treatment in Singapore for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and moderate to advanced liver fibrosis (F2–F3), as an adjunct to a reduced-calorie diet and increased physical activity..

诺和诺德宣布，新加坡卫生科学局（HSA）已批准Wegovy®（每周一次注射用司美格鲁肽2.4 mg），作为新加坡首个用于患有非肝硬化代谢功能障碍相关脂肪性肝炎（MASH，以前称为NASH）和中度至晚期肝纤维化（F2–F3）的成年人的治疗药物，作为低热量饮食和增加体力活动的辅助治疗。

Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly referred to as fatty liver disease, is associated with metabolic risk factors including obesity. MASH is the more serious, progressive form of MASLD, in which excess liver fat is accompanied by inflammation and liver-cell injury that can cause progressive scarring, or fibrosis.

代谢功能障碍相关脂肪性肝病（MASLD），通常称为脂肪肝，与包括肥胖在内的代谢风险因素相关。MASH 是 MASLD 的一种更严重、进展性的形式，其特征是肝脏脂肪过多并伴有炎症和肝细胞损伤，可导致进行性瘢痕形成，即纤维化。

MASH often develops without noticeable symptoms and, if untreated, can progress to cirrhosis or liver cancer. .

MASH 通常在无明显症状的情况下发展，若不加治疗，可能进展为肝硬化或肝癌。

In Singapore, the pattern of advanced liver disease is changing. Data from nearly 1,200 people with cirrhosis in SingHealth's Chronic Liver Disease Registry showed that MASH accounted for 39.8% of cirrhosis cases in 2024, surpassing hepatitis B at 23.5%.

在新加坡，晚期肝病的疾病谱正在发生变化。新加坡保健集团慢性肝病登记处近1,200名肝硬化患者的数据显示，2024年代谢功能障碍相关脂肪性肝炎（MASH）占肝硬化病例的39.8%，超过乙型肝炎的23.5%。